145 related articles for article (PubMed ID: 11735689)
1. Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents.
Volmar KE; Hutchins GM
Arch Pathol Lab Med; 2001 Dec; 125(12):1555-61. PubMed ID: 11735689
[TBL] [Abstract][Full Text] [Related]
2. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.
Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ
Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800
[TBL] [Abstract][Full Text] [Related]
3. Histologic changes in three explanted native cardiac valves following use of fenfluramines.
Steffee CH; Singh HK; Chitwood WR
Cardiovasc Pathol; 1999; 8(5):245-53. PubMed ID: 10533956
[TBL] [Abstract][Full Text] [Related]
4. Regression and progression of valvulopathy associated with fenfluramine and phentermine.
Dahl CF; Allen MR
Ann Intern Med; 2002 Mar; 136(6):489. PubMed ID: 11900508
[No Abstract] [Full Text] [Related]
5. Asymptomatic mitral and aortic valve disease is seen in half of the patients taking 'phen-fen'.
Griffen L; Anchors M
Arch Intern Med; 1998 Jan; 158(1):102. PubMed ID: 9437392
[No Abstract] [Full Text] [Related]
6. Valvular heart disease associated with fenfluramine-phentermine.
Connolly HM; Crary JL; McGoon MD; Hensrud DD; Edwards BS; Edwards WD; Schaff HV
N Engl J Med; 1997 Aug; 337(9):581-8. PubMed ID: 9271479
[TBL] [Abstract][Full Text] [Related]
7. The longitudinal effects of fenfluramine-phentermine use.
Fleming RM; Boyd LB
Angiology; 2007; 58(3):353-9. PubMed ID: 17626991
[TBL] [Abstract][Full Text] [Related]
8. Dose-effect of fenfluramine use on the severity of valvular heart disease among fen-phen patients with valvulopathy.
Li R; Serdula MK; Williamson DF; Bowman BA; Graham DJ; Green L
Int J Obes Relat Metab Disord; 1999 Sep; 23(9):926-8. PubMed ID: 10490797
[TBL] [Abstract][Full Text] [Related]
9. Silver lining to the cloud over anorexogen-related cardiac valvulopathy?
St John Sutton M
Ann Intern Med; 2001 Feb; 134(4):335-7. PubMed ID: 11182845
[No Abstract] [Full Text] [Related]
10. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.
Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE
N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087
[TBL] [Abstract][Full Text] [Related]
11. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities.
Jollis JG; Landolfo CK; Kisslo J; Constantine GD; Davis KD; Ryan T
Circulation; 2000 May; 101(17):2071-7. PubMed ID: 10790349
[TBL] [Abstract][Full Text] [Related]
12. Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months.
Burger AJ; Sherman HB; Charlamb MJ; Kim J; Asinas LA; Flickner SR; Blackburn GL
J Am Coll Cardiol; 1999 Oct; 34(4):1153-8. PubMed ID: 10520805
[TBL] [Abstract][Full Text] [Related]
13. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.
Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL
Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587
[TBL] [Abstract][Full Text] [Related]
14. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL
JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938
[TBL] [Abstract][Full Text] [Related]
15. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease.
Lepor NE; Gross SB; Daley WL; Samuels BA; Rizzo MJ; Luko SP; Hickey A; Buchbinder NA; Naqvi TZ
Am J Cardiol; 2000 Jul; 86(1):107-10. PubMed ID: 10867106
[No Abstract] [Full Text] [Related]
16. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.
Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT
N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086
[TBL] [Abstract][Full Text] [Related]
17. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.
Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL
JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496
[TBL] [Abstract][Full Text] [Related]
18. Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
Whigham LD; Dhurandhar NV; Rahko PS; Atkinson RL
Int J Obes (Lond); 2007 May; 31(5):850-7. PubMed ID: 17146452
[TBL] [Abstract][Full Text] [Related]
19. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.
Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB
Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737
[TBL] [Abstract][Full Text] [Related]
20. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.
Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT
N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
